Management Team

Jon P. Stonehouse

President, Chief Executive Officer

Jon Stonehouse, a pharmaceutical executive for more than 20 years, has strong commercialization, financial transaction, business development and management expertise. He most recently served as Senior Vice President of Corporate Development at Merck KGaA with responsibility for global licensing and business development, corporate mergers and acquisitions, corporate strategic planning and alliance management. Among his accomplishments, he was responsible for leading the effort to develop a strategy for Merck that significantly changed the company over the last four years. This culminated with the acquisition of Serono, S.A., the largest biotechnology company in Europe at the time of the agreement.

Stuart Grant

Senior Vice President, Chief Financial Officer

Stuart Grant joined the Senior Management Team at BioCryst in August of 2007. His recent experience with an established multi-national biotechnology company, coupled with his financial experience, add significantly to the depth of the BioCryst team. Prior to joining BioCryst, Mr. Grant was Chief Financial Officer at The Serono Group, based in Geneva, Switzerland. Operating as part of the leadership team, he was responsible for leading the Finance, Information Technology, and Communications functions, as well as driving the growth of profitability throughout the company. He was extensively involved in communicating strategy and tactics to the investor community. He has held a variety of Senior Operating and Financial positions in Europe and in the United States, and his drive and leadership skills will support the development of BioCryst in the next stages of the Company’s development.

David S. McCullough

Vice President, Strategic Planning, Commercialization and Corporate Development

David McCullough joined BioCryst in April, 2007. Prior to joining BioCryst Mr. McCullough served as Director, Global Corporate Development in the Ethical Pharmaceuticals Division at Merck KGaA in Darmstadt, Germany. In that position he was responsible for leading the company's efforts in evaluating the commercial value of specific product opportunities and in the case of the Serono SA acquisition, their entire company portfolio. Mr. McCullough led the commercial assessment of strategic and financial attractiveness of over 40 companies in oncology and other therapeutic areas. Prior to that position, Mr. McCullough was an integral part of the Business Operations and Market Research Team in the Oncology Business Unit of Eli Lilly and Company.

Mr. McCullough received his Bachelor of Science degree from Western Illinois University.

Yarlagadda S. Babu, Ph.D.

Vice President, Drug Discovery

Dr. Babu directs a team of crystallographers and oversees the drug design and computer modeling efforts of the company. Having joined the Company in 1988, Dr. Babu was BioCryst's first full-time employee. Prior to joining BioCryst, he served five years on the biochemistry faculty at the University of Alabama at Birmingham.

Walter G. Gowan, Ph.D.

VP Chemistry Manufacturing and Control

Dr. Walter Gowan joined BioCryst in September 2006. Dr. Gowan has more than 20 years of experience in managing pharmaceutical product development programs. His experience includes many dosage forms including oral solutions, oral suspensions, tablets, capsules and sterile products (IV, IM and SC). Dr. Gowan has experience in all stages of product development including formulation development, process development, clinical supplies manufacturing, scale up, process validation, technology transfer, and the resolution of manufacturing issues. Many of his projects have resulted in US and European regulatory filings as well as several products. Prior to joining BioCryst, Dr. Gowan held the position of Senior Director Pharmaceutical Sciences at Cubist Pharmaceuticals where he was responsible for managing the internal and external pharmaceutical product development programs. Prior to joining Cubist, Dr. Gowan held the position of Director Product Development at Solvay Pharmaceuticals where he supervised two product development groups and managed the internal and external development of product candidates. Dr. Gowan received his Ph.D. in Pharmaceutics, B.S. in Pharmacy and B.S. in Biology from the University of Texas.

Alane Barnes

General Counsel

Ms. Alane P. Barnes joined BioCryst in 2006. Prior to joining BioCryst, Ms. Barnes served as Senior Licensing Associate at the University of Alabama at Birmingham. From 1997, she was responsible for market and competitive analysis to determine intellectual property protection strategy, structuring and negotiation of strategic partnerships and collaborations, technology transfers, licenses and spin-out transactions including engagements for private financing. Ms. Barnes also served as a representative of UABRF and UAB at international biotech meetings and economic development meetings. From 1997 to 2003 Ms. Barnes practiced in a law firm and advised numerous companies on a broad range of issues including general corporate law, regulatory compliance, intellectual property, merger and acquisitions and shareholder agreements, health care law. Ms. Barnes graduated magna cum laude from Cumberland School of Law in 1997 and is a member of Curia Honoris. Ms. Barnes received both her B.S in Natural Science and a minor in Chemistry from the University of Alabama at Birmingham.

Elliott Berger, Ph.D.

Senior Vice President, Regulatory Affairs

Dr. Elliott Berger joined BioCryst in August 2007. Dr. Berger has more than 30 years of experience in the pharmaceutical industry, including over 25 years devoted to management of regulatory affairs supporting new drug and biologic development. Prior to joining BioCryst, he was Vice President, Regulatory Affairs and Quality Assurance, Head of Global Regulatory Strategy at EMD Pharmaceuticals, the North American subsidiary of Merck KGaA. As part of the EMD start-up team, Dr. Berger built and managed the EMD Regulatory Affairs, Clinical Quality Assurance and Drug Safety Groups, as well as the Global Regulatory Strategy Group. At EMD, Dr. Berger submitted and managed over 10 Investigational New Drug Applications in areas of oncology, diabetes, cardiovascular disease, and neurology. Dr. Berger also prepared and submitted the NDA for Cyanokit® which was approved within 6 months of submission to the FDA. Prior to EMD, Dr. Berger was a member of the Senior Executive Team at Astra Pharmaceuticals, most recently serving as Vice President, Regulatory Affairs.

Dr. Berger received both his Ph.D. and M.S. degrees in Biometrics as well as his B.A. degree in Mathematics from Temple University.

William P. Sheridan, MB BS

Chief Medical Officer

Dr. William Sheridan joined BioCryst in July 2008. Dr. Sheridan is a seasoned biotechnology professional, most recently serving as Vice President of North American Medical Affairs at Amgen, Inc. During his 15-year tenure at Amgen, Dr. Sheridan organized and led the company's US Medical Affairs function, making significant contributions to the successful launch of many compounds, including Aranesp®, Enbrel®, Kineret®, Neulasta® and Sensipar®. In addition to his most recent position, Dr. Sheridan held titles at the Vice President level at Amgen in International Medical Affairs, Global Health Economics and Outcomes Research, US Medical Affairs, and Product Development. He played an integral role in building Amgen's international medical affairs function and in forming the health economics and outcomes unit. Dr. Sheridan earned his MB BS degree (M.D. equivalent) at the University of Melbourne in Victoria. Dr. Sheridan is a board-certified fellow of the Royal Australasian College of Physicians (FRACP), with a sub-specialty in medical oncology.

Robert Stoner

Vice President, Human Resources

Mr. Robert Stoner joined BioCryst in January 2008. Mr. Stoner brings more than 25 years of progressive Human Resources experience to BioCryst, having worked in a diverse group of industries during his career. Prior to joining BioCryst, Mr. Stoner served as Senior Vice President Human Resources at Smith Breeden Associates, Inc. an institutional financial management company in Chapel Hill, North Carolina. Prior to joining Smith Breeden Associates, Mr. Stoner held the position of Vice President Human Resources at EMD Pharmaceuticals, the North American subsidiary of Merck KGaA. At EMD, Mr. Stoner was responsible for all human resource functions for multiple locations and was a member of the Global HR Team, coordinating and directing global HR initiatives within North America.

Mr. Stoner participated in and graduated from the Merck University Executive Management Program, attending Northwestern University, Kellogg School of Management, Hong Kong University of Science and Technology and INSEAD in Paris. Mr. Stoner received his B.S. in Business Administration from Southern Illinois University.

Board of Directors

Stephen R. Biggar, M.D., Ph.D. was appointed to the Board in October 2005. Dr. Biggar has served as a Partner at Baker Brothers Investments, a family of long-term investment funds for major university endowments and foundations, which is focused on publicly traded life sciences companies, since October 2006, served as Principal from April 2002 to October 2006 and served as an Associate from April 2000 to April 2002. Prior to joining Baker Brothers, Dr. Biggar received an M.D. and a Ph.D. in Immunology from Stanford University. He attended the University of Rochester where he achieved a B.S. degree in Genetics. Dr. Biggar serves as a director of one private biotechnology company.
Stanley C. Erck was elected a Director in December 2008. From 2000-2008, Mr. Erck served as President and Chief Executive Officer of Iomai Corporation, leading the company through an initial public offering and a merger with Intercell, an Austrian vaccine company, and through the development of a late-stage infectious disease product candidate. Prior to Iomai, Mr. Erck served as President and Chief Executive Officer of Procept, a publicly traded immunology company; as Vice President, Corporate Development at Integrated Genetics (now Genzyme), and in management positions within Baxter International. Mr. Erck currently sits on the Board of Directors of MacCyte and MdBio Foundation. He received his undergraduate degree from the University of Illinois and his Masters in Business Administration from the University of Chicago Graduate School of Business.
William W. Featheringill was elected a Director in May 1995. Mr. Featheringill is President, Chief Executive Officer and director, since 1973, of Private Capital Corporation, a venture capital company. He currently serves as Chairman of Electronic Healthcare Systems, Inc., a system solutions provider to the ambulatory care industry, since June 1995, and Momentum Business Solutions, Inc., a telecom and VoIP company, since May 2001. Mr. Featheringill is a Director of Altec Industries, Inc., Southern Research Institute and the Birmingham Museum of Art, and serves as a Trustee of Vanderbilt University. Mr. Featheringill received a BE in Mechanical Engineering from Vanderbilt University, a J.D. degree from the Columbia University School of Law and a M.B.A. from the Columbia University Graduate School of Business.
John L. Higgins was elected a Director in May 2004. Mr. Higgins is President and Chief Executive Officer of Ligand Pharmaceuticals Inc., a publicly traded biotech company, since January 2007 and has served as a director since February 2007. He was most recently Chief Financial Officer at the biotech company Connetics, since 1997, and also served as Executive Vice President, Finance and Administration and Corporate Development since January 2002 until its acquisition by Stiefel Laboratories, Inc. in December 2006. Before joining Connetics, he was a member of the executive management team at BioCryst. Before joining BioCryst in 1994, Mr. Higgins was a member of the healthcare banking team of Dillon, Read & Co. Inc., an investment banking firm. He received his A.B. from Colgate University.
Zola P. Horovitz, Ph.D. was elected a Director in August 1994. Dr. Horovitz was Vice President of Business Development and Planning at Bristol-Myers Squibb from 1991 until his retirement in April 1994 and previously was Vice President of Licensing at the same company from 1990 to 1991. Prior to that, he spent over 30 years with The Squibb Institute for Medical Research, most recently as Vice President Research, Planning, & Scientific Liaison. He has been an independent consultant in pharmaceutical sciences and business development since his retirement from Bristol-Myers Squibb in April 1994. He serves as non executive Chairman on the Board of Directors of Avigen, Inc. and GenVec, Inc., and also serves on the Boards of Directors of Genaera Pharmaceuticals, Inc., Palatin Technologies, Inc., DOV Pharmaceuticals, NitroMed, Inc. and Immunicon Corporation.
Beth C. Seidenberg, M.D. was appointed to the Board in December 2005. Dr. Seidenberg has served as Partner of Kleiner Perkins Caufield and Byers ("KPCB"), a venture capital firm, since May 2005. Prior to joining KPCB, Dr. Seidenberg served at Amgen, a biotechnology company, as Chief Medical Officer and Senior Vice President, Global Development from January 2002 to December 2004. She also served at Bristol-Myers Squibb Company, a pharmaceutical company, as Senior Vice President, Global Development from September 2001 to January 2002, Senior Vice President, Clinical Development & Life Cycle Management from May 2000 to September 2001 and Vice President, Clinical Immunology/Pulmonary/Dermatology from April 2000 to May 2000 and at Merck/Merck Research Laboratories as Vice President, Pulmonary-Immunology from July 1998 to March 2000, Executive Director from March 1996 to June 1998, Senior Director from September 1993 to February 1996 and also served as both Director and Associate Director of Clinical Pharmacology from September 1991 to August 1993 and from June 1989 to August 1991, respectively. She received her M.D. from University of Miami; completed post-doctoral training at Johns Hopkins Medical Center and specialty training in immunology and infectious diseases at the National Institutes of Health. Dr. Seidenberg also has a B.S. degree in Biology and Anthropology from Barnard College. Dr. Seidenberg was appointed to the Board as a designee of KPCB under a Nomination and Observer Agreement with the Company dated December 16, 2005.
Jon P. Stonehouse joined BioCryst in January 2007 as Chief Executive Officer and director. He was also named President in July 2007. Prior to joining the Company, he served as Senior Vice President of Corporate Development for Merck KGaA, a pharmaceutical company, since July 2002. His responsibilities included corporate mergers & acquisitions, global licensing and business development, corporate strategy and alliance management. In March of 2002, Mr. Stonehouse was appointed Vice President of Global Licensing and Business Development and Integration where he was responsible for the worldwide licensing and business development activities for the Ethical Pharmaceutical Division of Merck KGaA. Mr. Stonehouse joined EMD Pharmaceuticals, Inc. (the US Ethical Pharma division for Merck KGaA) in December 1999 as Vice President, Licensing and Business Development — Strategy & Integration and IT. Prior to joining Merck KGaA, he held a variety of roles at Astra Merck/AstraZeneca including: Customer Unit Director, Director, Marketing & Sales — IT, National Sales Manager, National Sales Director - Managed Healthcare, and Product Director — Omeprazole (the world's most widely prescribed prescription drug-at that time). Mr. Stonehouse started his career in the pharmaceutical industry as a Sales Representative, National Sales Trainer and District Sales Manager for Merck & Co., Inc. Mr. Stonehouse earned his BS in Microbiology at the University of Minnesota.

BioCryst’s people are dedicated to winning the fight against disease